Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced a definitive agreement to acquire Access Point Technologies EP (APT). APT, based in Minnesota, develops electrophysiology catheters used in cardiac ablation procedures. This acquisition enhances Stereotaxis' catheter development, manufacturing capabilities, and provides commercial synergies. The deal includes upfront and contingent payments in Stereotaxis common stock, with APT expected to contribute approximately $5 million in annual revenue post-acquisition. The transaction is subject to customary closing conditions and is anticipated to close in Q3 2024. The acquisition aligns with Stereotaxis' strategy to innovate in endovascular surgery and improve arrhythmia treatments.
Positive
Acquisition enhances catheter development and manufacturing capabilities.
Expected $5 million annual revenue contribution post-acquisition.
Strengthens Stereotaxis' position in endovascular surgery and arrhythmia treatments.
Commercial synergies anticipated between Stereotaxis and APT.
Acquisition pursued in a financially prudent and shareholder-friendly manner.
Negative
Acquisition is contingent on customary closing conditions.
All payments for the acquisition are in common stock, which could lead to shareholder dilution.
Integration risks associated with merging APT into Stereotaxi